14102 studies
Semaglutide (Sema), a potent glucagon-like peptide-1 receptor agonist, is widely used in the management of type 2 diabetes mellitus due to its glucose-lowering effects. Beyond this, Sema also exhibits antioxidative, anti-inflammatory, antiapoptotic,…
BACKGROUND: Diabetic retinopathy (DR) is a leading cause of acquired vision loss in middle-aged adults. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are widely used in the management of type 2 diabetes (T2D). Emerging evidence has suggested a…
AIMS: To evaluate the cost-effectiveness of liraglutide, semaglutide, tirzepatide, benaglutide, and lifestyle management for the treatment of obesity from the perspective of the Chinese healthcare system. MATERIALS AND METHODS: This study gathered cl…
AIMS: To evaluate the association between tirzepatide and the risk of developing erectile dysfunction (ED) in men with type 2 diabetes (T2D), compared with sitagliptin, injectable semaglutide, and dulaglutide. METHODS: This retrospective cohort study…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are crucial in managing type 2 diabetes mellitus (T2DM) and obesity. Agents like dulaglutide, semaglutide, and liraglutide mimic endogenous GLP-1, enhancing insulin secretion and promo…
To compare efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in subjects with type 2 diabetes (T2DM). Electronic databases were searched from inception to 2nd October 2024 for randomised controlled trials comparing GLP-1RAs…
AIMS: To compare major limb events in individuals with type 2 diabetes who initiated either injective or oral semaglutide versus other glucose-lowering therapies (GLT) in a real-world setting. MATERIALS AND METHODS: This was a single-centre retrospec…
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has transformed the treatment landscape for type 2 diabetes and obesity due to its robust efficacy and wide-ranging therapeutic benefits. This review outlines semaglutide's diverse me…
INTRODUCTION: Currently, limited guideline-directed medical therapies are available for heart failure (HF) with preserved and mildly reduced ejection fraction (EF). Both are associated with an increased risk of hospitalization and death, especially i…
We present the case of a female in her 20s with a history of obesity and obstructive sleep apnea (OSA) on continuous positive airway pressure (CPAP) therapy, who developed silent microaspiration pneumonitis and organising pneumonia (OP) following the…
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists have gained popularity after clinical trials demonstrated their weight-loss potential. The term "Ozempic® face" has been coined to describe the exaggerated volume loss from semaglutide the…
Cagrilintide (also known as 0833) is an amylin and calcitonin receptor agonist in clinical development for weight management and type-2-diabetes in a fixed-dose combination with semaglutide. Here, we introduce 0174-0839 (0839) as a tool compound for…
BACKGROUND: Type 2 diabetes (T2D) and chronic kidney disease (CKD) significantly increase the risk of cardiovascular events, including death and heart failure (HF). The FLOW trial demonstrated that semaglutide reduces all-cause death, cardiovascular…
CagriSema is a combination of amylin (cagrilintide) and glucagon-like peptide-1 (semaglutide) analogues being developed for weight management. Here, we show that CagriSema blunts metabolic adaptation in rats. Quantifying CagriSema's action on energy…
PURPOSE: Endoscopic sleeve gastroplasty (ESG) and GLP-1RA are proven obesity interventions with potential to aid patients who have MASLD. However, their comparative effectiveness remains unclear. This study aimed to compare ESG and semaglutide in MAS…
OBJECTIVE: The hormone peptide YY (PYY; cleaved into Y-selective form PYY) is an attractive candidate for use as a complementary pharmacotherapy for obesity along with glucagon-like peptide-1 (GLP-1) receptor agonists. This series of studies investig…
OBJECTIVE: To characterize the weight fluctuation and explore its influencing factors after glucagon-like peptide 1 receptor agonist (GLP-1RA) treatment in patients with overweight or obesity. METHODS: This retrospective cohort study enrolled 679 pat…
Obesity is a chronic, recurrent and progressive disease that is a major public health issue, contributing to disability, morbidity and mortality worldwide. The global increase in obesity prevalence has been accompanied by an increase in weight-relate…
Several incretin hormone therapies have been clinically approved and have revolutionized the treatment of diabetes and obesity. Promising therapeutics include semaglutide (Ozempic and Wegovy), an agonist for glucagon-like peptide-1 (GLP-1) receptor,…
PURPOSE: This study aimed to investigate changes in muscle mass and strength among older adults with type 2 diabetes who were treated with Semaglutide. METHODS: This was a retrospective cohort study comparing elderly patients with type 2 diabetes rec…